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Abstract: OBJECTIVE Takotsubo syndrome (TTS) is characterized by acute left ventricular dysfunction,
which can contribute to intraventricular thrombus and embolism. Still, prevalence and clinical impact of
thrombus formation and embolic events on outcome of TTS patients remain unclear. This study aimed
to investigate clinical features and outcomes of patients with and without intraventricular thrombus or
embolism. Additionally, factors associated with thrombus formation or embolism, as well as predictors for
mortality, were identified. Approach and Results: TTS patients enrolled in the International Takotsubo
Registry at 28 centers in Australia, Europe, and the United States were dichotomized according to the
occurrence/absence of intraventricular thrombus or embolism. Patients with intraventricular thrombus or
embolism were defined as the ThrombEmb group. Of 1676 TTS patients, 56 (3.3%) patients developed
intraventricular thrombus and/or embolism following TTS diagnosis (median time interval, 2.0 days
[range, 0-38 days]). Patients in the ThrombEmb group had a different clinical profile including lower
left ventricular ejection fraction, higher prevalence of the apical type, elevated levels of troponin and
inflammatory markers, and higher prevalence of vascular disease. In a Firth bias-reduced penalized-
likelihood logistic regression model apical type, left ventricular ejection fraction ฀30%, previous vascular
disease, and a white blood cell count on admission >10×103 cells/฀L emerged as independent predictors
for thrombus formation or embolism. CONCLUSIONS Intraventricular thrombus or embolism occur in
3.3% of patients in the acute phase of TTS. A simple risk score including clinical parameters associated
with intraventricular thrombus formation or embolism identifies patients at increased risk. CLINICAL
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CLINICAL AND POPULATION STUDIES
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OBJECTIVE: Takotsubo syndrome (TTS) is characterized by acute left ventricular dysfunction, which can contribute to intraventricular 
thrombus and embolism. Still, prevalence and clinical impact of thrombus formation and embolic events on outcome of TTS patients 
remain unclear. This study aimed to investigate clinical features and outcomes of patients with and without intraventricular thrombus 
or embolism. Additionally, factors associated with thrombus formation or embolism, as well as predictors for mortality, were identified.
APPROACH AND RESULTS: TTS patients enrolled in the International Takotsubo Registry at 28 centers in Australia, Europe, and the 
United States were dichotomized according to the occurrence/absence of intraventricular thrombus or embolism. Patients with 
intraventricular thrombus or embolism were defined as the ThrombEmb group. Of 1676 TTS patients, 56 (3.3%) patients developed 
intraventricular thrombus and/or embolism following TTS diagnosis (median time interval, 2.0 days [range, 0–38 days]). Patients 
in the ThrombEmb group had a different clinical profile including lower left ventricular ejection fraction, higher prevalence of the 
apical type, elevated levels of troponin and inflammatory markers, and higher prevalence of vascular disease. In a Firth bias-reduced 
penalized-likelihood logistic regression model apical type, left ventricular ejection fraction ≤30%, previous vascular disease, and a 
white blood cell count on admission >10×103 cells/µL emerged as independent predictors for thrombus formation or embolism.
CONCLUSIONS: Intraventricular thrombus or embolism occur in 3.3% of patients in the acute phase of TTS. A simple risk score 
including clinical parameters associated with intraventricular thrombus formation or embolism identifies patients at increased risk.
CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT01947621.
VISUAL OVERVIEW: An online visual overview is available for this article. 
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T
akotsubo syndrome (TTS) is increasingly being rec-
ognized as an important differential diagnosis in 
patients presenting with acute chest pain or heart 
failure symptoms.1–6 Although initially considered as 
rather benign condition, TTS is associated with substan-
tial morbidity and mortality.1,7–11 Indeed, severe in-hospital 
complications including arrhythmias,12 left ventricular 
(LV) outflow tract obstruction,13 cardiogenic shock,14 LV 
rupture,15 and death1 were reported, and rates of adverse 
events are comparable to those of patients with acute 
coronary syndromes.1,7 Case reports and small obser-
vational studies have pointed toward the occurrence of 
thromboembolic complications in TTS patients.16–21 These 
studies reported a wide ranging prevalence of 2.2% to 
12.2% for thrombus formation and embolism,22,23 but the 
sequel of thrombus or embolic events associated with 
TTS are uncertain and have not yet been investigated in 
a large patients’ cohort.
The aim of the present study was, therefore, to assess 
the prevalence, clinical correlates, and outcomes of 
patients with intraventricular thrombus or embolism in 
TTS using data from the International Takotsubo (Inter-
TAK) Registry (www.takotsubo-registry.com).
MATERIALS AND METHODS
The design of the InterTAK Registry has previously been 
described elsewhere.1,24 One thousand six hundred seventy-six 
patients were selected for the present study according to avail-
ability of comprehensive imaging data regarding the presence 
or absence of intraventricular thrombus or embolism. TTS was 
defined based on InterTAK Diagnostic Criteria.6 The authors 
declare that all supporting data are available within the article 
and its online-only Data Supplement.
Data on demographic characteristics, clinical presentation, 
triggering factors, admission and discharge medication, comor-
bidities (including vascular disease such as stroke or transient 
ischemic attack, myocardial infarction, peripheral artery dis-
ease, or aortic plaque), laboratory values, electrographic abnor-
malities, and imaging findings (echocardiography, coronary 
angiography, ventriculography, and cardiac magnetic resonance 
imaging [MRI]) along with short- and long-term outcomes 
were collected. In-hospital complications were defined as a 
composite of cardiogenic shock, ventricular tachycardia, and 
death. Follow-up was conducted through telephone interviews, 
clinical visits, or perusal of medical records.1,2 The median fol-
low-up time was 169 days (interquartile range, 8–1041 days).
TTS patients were dichotomized according to the presence 
or absence of intraventricular thrombus or embolism. Patients 
in whom a preceding TTS event could be identified as the etio-
logical cause of thrombus formation or embolism were defined 
as the ThrombEmb group (consisting of left or right ventricular 
thrombus formation, ischemic stroke, splenic infarction, or coro-
nary embolus). In cases in which acute stroke preceded the 
TTS event, stroke was defined as a physical triggering factor, 
and these cases were not included in the ThrombEmb group. 
Furthermore, patients with atrial fibrillation who had an embolic 
event were excluded from the study since it cannot be deter-
mined whether the embolism was due to atrial fibrillation or 
TTS. For the diagnosis of ventricular thrombus, established cri-
teria were applied.25 Clinical characteristics and outcomes were 
compared between groups, and risk factors for thrombus for-
mation or embolism, as well as predictors of 6-month mortality, 
were identified. In addition, a subanalysis to assess differences 
in the clinical profile and outcomes of TTS patients with ventric-
ular thrombus and TTS patients with embolism was conducted.
Statistical Analysis
Continuous variables are given as mean±SD or median with 
interquartile range and were tested for differences with the 
Student t test or Mann-Whitney U test. Categorical variables 
are summarized as frequencies and percentages and were 
analyzed using Pearson χ2 test or Fisher exact test.
Clinical variables that were significantly different at base-
line comparison between groups and might have an impact on 
thrombus formation were included in Firth bias-reduced penal-
ized-likelihood logistic regression model26,27 to identify clinical 
parameters independently associated with thrombus formation 
or embolic events. Firth logistic regression has become a stan-
dard approach to the problem of separation in logistic regres-
sion with rare events. It is defined by logL×(β)=logL(β)+A(β) 
with A(β)=1/2logdet(I(β)) where I (β) is the Fisher information 
matrix and L (β) is the likelihood.28 Two simple modifications of 
Firth logistic regression resulting in unbiased predicted prob-
abilities were given by Puhr et al.27 The first corrects the pre-
dicted probabilities by a post hoc adjustment of the intercept. 
The other is based on an alternative formulation of Firth penal-
ization as an iterative data augmentation procedure.
A prognostic index (InterTAK Thrombus Prognostic Index) 
and a risk score (InterTAK Thrombus Risk Score) were calculated 
using the coefficients of Firth logistic regression model. The coef-
ficients were transformed into item scores and added up to a total 
score, the InterTAK Thrombus Prognostic Index. The item scores 
Nonstandard Abbreviations and Acronyms
CRP C-reactive protein
HR hazard ratio
InterTAK registry  International Takotsubo registry
LV left ventricular
LVEF left ventricular ejection fraction
ThrombEmb thrombotic or embolic event
TTS takotsubo syndrome
WBC white blood cell count
Highlights
• Thrombus formation and embolic events occur in 
≈3% of patients with takotsubo syndrome.
• The International Takotsubo Thrombus Risk Score 
presents a valuable tool to identify patients at risk 
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were calculated by dividing each coefficient with the smallest 
coefficient in the model and then by rounding to the nearest 
0.5. Internal validation was performed using 500 bootstrapping 
samples. The InterTAK Thrombus Prognostic Index was divided 
into different risk groups with respect to optimal cutoffs that form 
the InterTAK Thrombus Risk Score. Missing values were replaced 
by multiple imputation before logistic regression with Firth bias 
correction. To assess the impact of thrombotic or embolic events 
on 6-month mortality, a Cox-regression analysis was executed 
including parameters that had statistical significance at baseline 
comparison. Hazard ratios (HRs) are reported with 95% CIs.
A 2-sided P of <0.05 was considered to indicate statisti-
cal significance. Statistical analysis was performed using IBM 
SPSS Statistics, version 24.0 and 25.0 (IBM Corp, Armonk, 
NY), and R, version 3.5.1 (R Foundation), and graphs were gen-
erated using Prism 8 (GraphPad, La Jolla, CA).
RESULTS
Study Population
Overall, 1676 patients were included in the pres-
ent study. The clinical course was complicated by 
intraventricular thrombus or embolism in 56 patients 
(3.3%) at a median time interval of 2.0 days (range, 
0–38 days) following TTS event (Figure 1). Among the 
56 patients, 38 (67.9%) had ventricular thrombus of 
whom 36 (64.3%) had LV thrombus, 1 (1.8%) had right 
ventricular thrombus, and 1 (1.8%) had LV and right 
ventricular thrombus. Furthermore, 13 (23.2%) had 
ischemic stroke, and 1 (1.8%) had coronary thrombus. 
In 4 patients (7.2%), thrombus formation or thrombus 
was observed in >1 location. As such, 1 (1.8%) had 
ischemic stroke and splenic infarction, and 3 (5.4%) 
patients had LV thrombus and ischemic stroke (Fig-
ure 2). A detailed description on the occurrence and 
type of embolic events is presented in Figure I in the 
online-only Data Supplement.
Clinical, laboratory, and electrocardiographic char-
acteristics are shown in Table 1. Age, sex, and preva-
lence of triggering factors did not differ between the 
ThrombEmb and the non-ThrombEmb groups. Patients 
in the ThrombEmb group more frequently presented with 
the apical TTS type (91.1% versus 70.1%; P<0.001).
Figure 1. Temporal occurrence 
of intraventricular thrombus or 
embolism in takotsubo syndrome 
(TTS).
Figure 2. Of 1676 patients studied, 56 
had thrombotic or embolic events, 38 
patients had ventricular thrombi, and 
13 patients had embolism.  
In 5 patients, thrombotic or embolic 
events were observed in >1 location 
(shaded areas). LV indicates left ventricle; 
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 (n=1620) P Value
Demographics
 Female sex, n/total n (%) 47/56 (83.9) 1463/1620 (90.3) 0.12
 Age, y 67.0±13.4 (n=56) 67.1±12.8 (n=1620) 0.96
 Body mass index, kg/m2 25.3±5.8 (n=38) 25.1±5.4 (n=1201) 0.99
Triggers, n/total n (%)
 Physical trigger 27/56 (48.2) 602/1620 (37.2) 0.09
 Emotional trigger 12/56 (21.4) 486/1620 (30.0) 0.17
 Both emotional and physical trigger 3/56 (5.4) 119/1620 (7.3) 0.79
 No evident trigger 14/56 (25.0) 413/1620 (25.5) 0.93
Takotsubo type, n/total n (%)
 Apical type 51/56 (91.1) 1135/1620 (70.1) <0.001
Cardiac biomarkers, median (IQR)
 Troponin on admission, multiple of ULN* 16.75 (4.27–44.60), n=45 8.04 (2.68–22.34), n=1305 0.028
 Troponin maximum, multiple of ULN* 27.36 (9.00–80.00), n=47 13.73 (5.13–35.78), n=1354 0.004
 Creatine kinase on admission, multiple of ULN 0.73 (0.49–1.50), n=34 0.87 (0.54–1.41), n=1150 0.93
 Creatine kinase maximum, multiple of ULN 1.11 (0.73–1.98), n=35 1.11 (0.65–1.97), n=1189 0.47
 BNP on admission, multiple of ULN† 7.88 (3.02–12.86), n=17 6.20 (2.22–16.74), n=467 0.66
 BNP maximum, multiple of ULN† 11.68 (5.69–29.28), n=26 10.09 (4.53–24.37), n=601 0.41
Inflammatory markers, median (IQR)
 CRP on admission, mg/L 6.55 (3.12–22.68), n=32 3.80 (1.30–11.98), n=1039 0.014
 CRP maximum, mg/L 22.45 (4.18–133.98), n=36 8.90 (2.70–41.47), n=1140 0.017
 WBC on admission, 103/µL 11.50 (9.90–16.10), n=47 9.67 (7.47–12.55), n=1402 <0.001
 WBC maximum, 103/µL 12.70 (10.60–18.20), n=51 10.50 (8.20–13.56), n=1442 <0.001
Lipid status, median (IQR)
 Triglyceride, mmol/L 1.33 (1.00–1.62), n=23 1.11 (0.83–1.60), n=856 0.29
 Cholesterol, mmol/L 4.74 (3.70–5.44), n=23 4.80 (3.94–5.57), n=869 0.57
 HDL cholesterol, mmol/L 1.31 (1.12–1.51), n=20 1.45 (1.14–1.80), n=758 0.25
 LDL cholesterol, mmol/L 3.02 (2.41–3.65), n=16 2.70 (2.00–3.40), n=717 0.27
ECG on admission, n/total n (%)
 Atrial fibrillation 5/46 (10.9) 87/1425 (6.1) 0.20
 ST-segment elevation 22/46 (47.8) 591/1425 (41.5) 0.39
 QTc, ms 460.4±43.6 (n=34) 458.3±47.6 (n=1150) 0.58
Hemodynamics, mean±SD (n)
 Heart rate, bpm 96.2±20.5 (n=40) 87.1±21.8 (n=1246) 0.005
 Systolic blood pressure, mm Hg 130.5±27.5 (n=43) 130.8±28.4 (n=1267) 0.92
 Diastolic blood pressure, mm Hg 76.6±13.8 (n=42) 76.4±16.8 (n=1241) 0.85
 LVEF, %‡ 38.3±12.1 (n=47) 40.9±11.6 (n=1446) 0.043
Coexisting medical condition, n/total n (%)
 Hypertension 32/55 (58.6) 1067/ 1590 (67.1) 0.17
 Diabetes mellitus 4/55 (7.3) 256/1604 (16.0) 0.08
 Current smoking 10/51 (19.6) 311/1525 (20.4) 0.89
 Hypercholesterolemia 13/55 (23.6) 516/1559 (33.1) 0.14
 Positive family history 6/41 (14.6) 272/1361 (20.0) 0.40
 Previous vascular disease§ 19/49 (38.8) 218/1478 (14.7) <0.001
  Stroke or TIA 10/51 (19.6) 103/1484 (6.9) 0.003
  PAD or aortic plaques 6/53 (11.3) 54/1612 (3.3) 0.010
  Myocardial infarction 6/54 (11.1) 74/1576 (4.7) 0.05
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Cardiac troponin levels on admission and peak tro-
ponin levels were significantly higher in the ThrombEmb 
as compared with the non-ThrombEmb group (Table 1). 
White blood cell count (WBC) counts on admission and 
corresponding peak WBC were also increased in the 
ThrombEmb group. Similarly, CRP (C-reactive protein) 
levels on admission and corresponding peak CRP levels 
were higher in the ThrombEmb group (Table 1).
Compared with patients in the non-ThrombEmb group, 
patients in the ThrombEmb group had a higher heart rate 
(96.2±20.5 bpm versus 87.1±21.8 bpm; P=0.005). There 
were no significant differences between the 2 groups in 
terms of the prevalence of ST-segment elevation or QTc 
prolongation. LV ejection fraction (LVEF) on admission 
(38.3±12.1% versus 40.9±11.6%; P=0.043) was lower in 
the ThrombEmb group compared with the non-ThrombEmb 
group. Patients in the ThrombEmb group had a higher 
prevalence of prior vascular disease (ie, transient ischemic 
attack/stroke, myocardial infarction, peripheral artery dis-
ease, or aortic plaques; 38.8% versus 14.7%; P<0.001). 
Cardiovascular medications on admission were balanced 
between groups and none of the patients in the ThrombEmb 
group was admitted with oral anticoagulants compared with 
4.2% in the non-ThrombEmb group (P=0.40).
A subanalysis comparing TTS patients with ventricu-
lar thrombus and embolism demonstrated no differences 
in clinical features and outcomes. At discharge, patients 
with ventricular thrombus received more frequently anti-
coagulants compared with patients with embolism (70.6% 
versus 26.7%; P=0.004; Table I in the online-only Data 
Supplement; Figure II in the online-only Data Supplement).
Clinical Parameters Associated With Thrombus 
Formation or Embolism—the InterTAK Thrombus 
Risk Score
In a multivariate penalized maximum likelihood estima-
tion analysis, apical TTS, previous vascular disease, 
LVEF ≤30%, and WBC on admission >10×103 cells/µL 
emerged as independent predictors of thrombus forma-
tion. An internal validation with 500 bootstrap samples 
showed that the results are stable and reliable with the 
following β-coefficients: apical TTS (1.13 [95% CI, 0.32–
2.15]; P=0.005), previous vascular disease (1.31 [95% 
CI, 0.73–1.87]; P<0.001), LVEF ≤30% (1.10 [95% CI, 
0.55–1.65]; P<0.001), and first WBC >10×103 cells/µL 
(0.78 [95% CI, 0.20–1.39]; P=0.007).
The C index of Firth penalized maximum likelihood 
estimation as a measure of goodness of fit for throm-
botic or embolic event is 0.77 ([95% CI, 0.72–0.84]; 
P<0.001). The item scores of the InterTAK Prognostic 
Index (Figure 3A and 3B) based on the 4 significant 
coefficients are defined as follows: 1.5 points for api-
cal TTS, 1.5 points for prior vascular disease, 1.5 points 
for LVEF ≤30%, and 1 point for WBC on admission 
>10×103 cells/µL. The InterTAK Prognostic Index for a 
patient is the sum of the corresponding item scores (min-
imum, 0; maximum, 5.5). An optimal cutoff value of the 
score is 3 dividing the patients into low (≤3) and high risk 
(>3) forming the corresponding risk score. Of the TTS 
patients, 83.1% were in the low- and 16.9% in the high-
risk group. Of the low-risk patients, 1.7% and 11.3% of 
the high-risk patients had a thrombotic or embolic event. 
None of the patients with 0 score points (n=204, 12.2%) 
had an event but 15.6% of patients with 5.5 score points 
(n=32). Furthermore, only 2 (0.5%) of 421 patients 
with LVEF >30% and atypical TTS had a thrombotic or 
embolic event. The corresponding area under the ROC 
curve is 0.78 with SE of 0.030 and asymptotic 95% CI 
of 0.72–0.83; P<0.001.
Clinical Outcomes
Rates of in-hospital complications (22.2% versus 12.6.%; 
P=0.039) such as cardiogenic shock (17.9% versus 
9.6%; P=0.040) were higher in the ThrombEmb group as 
Medication on admission, n/total n (%)
 ACE inhibitor or ARB 17/38 (44.7) 504/1301 (38.7) 0.46
 β-Blocker 15/38 (39.5) 407/1301 (31.3) 0.28
 Calcium-channel antagonist 1/37 (2.7) 99/1295 (7.6) 0.52
 Statin 6/37 (16.2) 264/1295 (20.4) 0.53
 Aspirin 14/37 (37.8) 451/1295 (34.8) 0.71
 ADP antagonist 9/37 (24.3) 102/1295 (7.9) 0.002
 Anticoagulants 0/37 (0.0) 54/1295 (4.2) 0.40
ACE indicates angiotensin-converting-enzyme; ARB, angiotensin receptor blocker; BNP, brain natriuretic peptide; CRP, C-reactive protein; HDL, 
high-density lipoprotein; IQR, interquartile range; LDL, low-density lipoprotein; LVEF, left ventricular ejection fraction; PAD, peripheral artery disease; 
QTc, QT interval corrected for heart rate; ThrombEmb, thrombotic or embolic event; TIA, transient ischemic attack; ULN, upper limit of the normal 
range; and WBC, white blood cell count.
*Including upper limits of the normal range for troponin T, high-sensitivity troponin T, and troponin I.
†Including upper limits of the normal range for brain natriuretic peptide and the N terminus of prohormone brain natriuretic peptide.
‡Data obtained during catheterization or echocardiography; if both results were available, data from catheterization were used.
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compared with the non-ThrombEmb group. Furthermore, 
patients in the ThrombEmb group required more often 
acute cardiac care measures (35.7% versus 20.4%; 
P=0.005) such as invasive or noninvasive ventilation 
(30.4% versus 17.1%; P=0.010) as well as catechol-
amine administration (23.2% versus 12.7%; P=0.021; 
Table 2). At multivariable Cox-regression analysis, LVEF 
≤30% (HR, 2.72 [95% CI, 1.88–3.95]; P<0.0001), heart 
rate >94bpm (HR, 1.73 [95% CI, 1.19–2.52]; P=0.004), 
first WBC >10×103 cells/µL (HR, 2.05 [95% CI, 1.39–
3.03]; P<0.001), and cancer (HR, 1.96 [95% CI, 1.32–
2.87]; P=0.001) emerged as independent predictors of 
6-months mortality (Figure III in the online-only Data 
Supplement).
DISCUSSION
This study analyzed the prevalence, clinical correlates, 
and outcomes of intraventricular thrombus or embolism in 
a large cohort of patients with TTS. The main findings are: 
(1) Intraventricular thrombus and/or embolism occur with 
a prevalence of 3.3%; (2) intraventricular thrombus are 
associated with clinically relevant embolic events in dif-
ferent organs; (3) intraventricular thrombus and embolic 
events occur at a median time interval of 2 days after TTS; 
(4) the apical form of TTS, severe LV systolic dysfunction 
prior vascular disease and an elevated WBC are clinical 
parameters associated with intraventricular thrombus for-
mation and/or embolic events in TTS.
Thromboembolic events may complicate the course 
following a TTS, particularly during the acute phase when 
LV function is still depressed. Besides blood stasis due to 
myocardial stunning and regional hypo-/akinesia, endo-
thelial activation and systemic hypercoagulability may 
promote thrombus formation in TTS patients.29 Patients 
presenting with the typical form of TTS seem to be partic-
ularly vulnerable to ventricular thrombus formation, prob-
ably owing to the larger amount of myocardium affected 






In-hospital complications, n/total n (%) 12/54 (22.2) 198/1569 (12.6) 0.039
 Cardiogenic shock 10/56 (17.9) 154/1611 (9.6) 0.040
 Ventricular tachycardia 4/54 (7.4) 40/1563 (2.6) 0.06
 Death 4/56 (7.1) 73/1620 (4.5) 0.32
Acute cardiac care treatment, n/total n (%) 20/56 (35.7) 328/1611 (20.4) 0.005
 Intra-aortic balloon pump 4/56 (7.1) 39/1611 (2.4) 0.053
 Invasive or noninvasive ventilation 17/56 (30.4) 275/1612 (17.1) 0.010
 Cardiopulmonary resuscitation 4/56 (7.1) 94/1620 (5.8) 0.57
 Catecholamine use 13/56 (23.2) 204/1612 (12.7) 0.021
ThrombEmb indicates thrombotic or embolic event.
Figure 3. InterTAK Thrombus Risk 
Score.  
A, International Takotsubo (InterTAK) 
prognostic index showing a progressive 
increase in risk with increasing score 
points. B, Variables included in the 
InterTAK Thrombus Risk Score. A cutoff of 
3 classifies patients in low- and high-risk 
categories.LVEF indicates left ventricular 
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and the more pronounced reduction of LV systolic func-
tion observed during the acute phase. A recent study 
found a LV thrombus prevalence of 2.2% in TTS with all 
thrombus events occurring in apical TTS cases, corrobo-
rating the association between apical TTS and thrombus 
formation.23 Similarly, LV thrombus formation following an 
acute myocardial infarction is mainly observed when the 
anterior LV wall is affected.30–32
The relation between stroke and TTS is complex 
as it may both be a trigger and a complication of this 
condition; indeed, neurological events such as ischemic 
stroke may induce an acute TTS episode,33–35 but may 
also complicate the course of TTS as observed in this 
study. Whether cardio-embolism represents the predomi-
nant cause of ischemic stroke in TTS patients or whether 
other mechanisms may also be involved such as cerebral 
vasospasm remains to be determined.
Interestingly, inflammatory biomarkers were signifi-
cantly elevated in TTS patients with thrombotic or embolic 
complications. Although this might be an epiphenomenon 
as embolic occlusion of a major artery with tissue isch-
emia and necrosis may itself activate inflammatory path-
ways, cytokines released from WBCs can promote or 
maintain thrombus formation in TTS. Indeed, interleukins, 
tumor necrosis factor alpha and other inflammatory mol-
ecules induce tissue factor expression in endothelial cell 
thereby activation the coagulation cascade.36 In line with 
this interpretation, increased CRP levels and WBC have 
been linked to LV thrombus formation also in patients with 
large anterior myocardial infarction.37
Results of the multivariable Cox-regression suggest 
that the higher rate of adverse events in patients is attrib-
uted to clinical parameters such as LVEF ≤30%, heart 
rate >94bpm, first WBC count >10×103 cells/µL, and 
malignancies and not to the thrombotic and/or embolic 
event per se.
The recent literature offers little guidance for the 
management of TTS patients with intraventricular throm-
bus as randomized trials are lacking. Given the potential 
complications which can be associated with thrombotic 
or embolic events early diagnosis is important to assure 
optimal medical care. Importantly, our study provides 
a useful risk stratification tool which may assist in the 
identification of patients at increased thrombotic and/
or embolic risk and in need for intense monitoring and 
follow-up. The proposed risk score, including the 4 vari-
ables apical form of TTS, severe LV systolic dysfunction, 
elevated WBC levels and prior vascular disease has the 
advantage of providing an easy applicable bedside test. 
Close monitoring may include serial echocardiography 
to detect clinically silent ventricular thrombus formation 
before devastating embolic complications, particularly 
during the first days following the acute TTS event when 
the risk appears to be highest. Contrast echocardiog-
raphy and cardiac MRI are sensitive methods to detect 
ventricular thrombus and may be considered in patients 
with a high-risk score. In the presence of LV thrombus 
anticoagulation therapy might be considered on an indi-
vidual basis.
Limitations
Some limitations need to be considered. First, this study 
has the limitations inherent to an observational and partly 
retrospective registry. Second, intraventricular thrombus 
formation or embolic events were not prespecified vari-
ables, and diagnosis was based on patient records and 
different imaging modalities including transthoracic echo-
cardiography and cardiac MRI. Furthermore, systematic 
MRI assessment was not performed in all patients since 
data went back to 1998 where MRI was not broadly and 
systematically available. Third, as the InterTAK Registry 
is an observational study, no fixed imaging time points 
were set. Therefore, the impact of timing on the diagno-
sis of ventricular thrombi remains unclear. The real prev-
alence of ventricular thrombi might be higher than the 
one reported herein if clinically silent thrombi remained 
undetected.
Conclusions
Intraventricular thrombus and embolism occur in 3.3% of 
patients with TTS during the acute phase. A simple bed-
side risk score including clinical parameters associated 
with intraventricular thrombus formation and embolism 
such as the apical TTS, low LVEF. Prior vascular disease 
and elevated WBC improves the thrombotic risk assess-
ment in TTS patients. Patients in the high-risk group may 
benefit from a more intense follow-up.
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